2022
DOI: 10.1007/s00134-022-06754-6
|View full text |Cite
|
Sign up to set email alerts
|

Shorter might not always be better: the case for longer antibiotic therapy for Pseudomonas aeruginosa pneumonia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0
1

Year Published

2022
2022
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 4 publications
0
1
0
1
Order By: Relevance
“…Surprisingly, a lower recurrence rate was seen in the patients who received the shorter antibiotic treatment. Chastre et al results were supported by Bouglé et al in 2022, which did not demonstrate non-inferiority of eight days of antibiotic treatment compared to fifteen days but was met with criticism [ [11] , [12] , [13] ].…”
Section: Discussionmentioning
confidence: 96%
“…Surprisingly, a lower recurrence rate was seen in the patients who received the shorter antibiotic treatment. Chastre et al results were supported by Bouglé et al in 2022, which did not demonstrate non-inferiority of eight days of antibiotic treatment compared to fifteen days but was met with criticism [ [11] , [12] , [13] ].…”
Section: Discussionmentioning
confidence: 96%
“…Unter folgenden Umständen kann eine Verlängerung derTherapiedauer bei bakterieller HAP dennoch empfehlenswert sein[6,26]:Ob bei einer VAP mit Nachweis von Pseudomonas die Therapiedauer generell von 8 auf 15 Tage prolongiert werden soll, ist unverändert umstritten. Eine aktuelle randomisiert, kontrollierte, multizentrische Studie mit 186 ICU-Patient*innen bestätigte jedoch erneut, dass eine lediglich 8-tägige Antibiose die Rezidivrate bei einer Pseudomonas-VAP erhöht und auch mit einem tendenziellen Anstieg der Mortalität assoziiert ist[27,28].Tab 1.…”
unclassified